['ankylosing spondylitis']
['placebo', 'golimumab']

        Inclusion Criteria:

          -  Participants with diagnosis of definite ankylosing spondylitis for at least 3 months
             based on modified New York radiographic and clinical criteria

          -  Participants with symptoms of active disease at screening and at baseline

          -  Participant has either an inadequate response to at least 2 non-steroidal
             anti-inflammatory drugs (NSAID) over a 4 week period in total with maximal recommended
             doses of NSAIDs, or is unable to receive a full 4 weeks of maximal NSAID therapy
             because of intolerance, toxicity, or contraindications to NSAIDs

          -  Participants with C- reactive protein (CRP) level of greater than or equal to (>=) 0.3
             milligram per deciliter (mg/dL) at screening

          -  Additional protocol-defined inclusion criteria apply

        Exclusion Criteria:

          -  Participant with other inflammatory diseases that might confound the evaluations of
             benefit from the golimumab therapy

          -  Pregnant or lactating females

          -  Participants with chest radiograph within 3 months prior to the first administration
             of study agent that shows an abnormality suggestive of a malignancy or current active
             infection, including tuberculosis

          -  Participants who had a serious infection (including but not limited to, hepatitis,
             pneumonia, sepsis, or pyelonephritis), or have been hospitalized for an infection, or
             have been treated with intravenous (IV) antibiotics for an infection within 2 months
             prior to first administration of study agent

          -  Additional protocol-defined exclusion criteria apply
      